Skip to main content

Gossamer Bio, Inc 8-K, filed Nov 10, 2026

Gossamer Bio, Inc. (GOSS)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Gossamer Bio, Inc filed this 8-K on November 10, 2026.

Gossamer Bio submitted its first Seralutinib NDA to the FDA in September 2026; cash, cash equivalents and marketable securities totaled $51.2 million as of September 30, 2026, and quarterly net loss was $48.1 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits